Track topics on Twitter Track topics that are important to you
Targeted Granzyme Immunotherapy Poster Presented 2018 AACR Annual PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Targeted Granzyme Immunotherapy Poster Presented 2018 AACR Annual articles that have been published worldwide.
We have published hundreds of Targeted Granzyme Immunotherapy Poster Presented 2018 AACR Annual news stories on BioPortfolio along with dozens of Targeted Granzyme Immunotherapy Poster Presented 2018 AACR Annual Clinical Trials and PubMed Articles about Targeted Granzyme Immunotherapy Poster Presented 2018 AACR Annual for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Targeted Granzyme Immunotherapy Poster Presented 2018 AACR Annual Companies in our database. You can also find out about relevant Targeted Granzyme Immunotherapy Poster Presented 2018 AACR Annual Drugs and Medications on this site too.
and case study poster sessions will be conducted during the 2018 College of American Pathologists Annual Meeting (CAP18), which is scheduled for October 20 to 24, 2018. The meeting will take place at the Hyatt Regency, Chicago, Illinois. The poster sessions will occur in the CAP18 Exhibit Hall. Specific dates and times for each poster session are listed below; "poster focus" times are dedicated poster viewing periods. Also shown before each poster session are the subject areas that will be presented.
The year 2018 has been incredibly prolific regarding novelties. Several studies have given impressive results and offer new anticancer perspectives. Immunotherapy is gaining more and more place defining a new standard of care for different types of cancer. In parallel with a new approach combining immunotherapy and chemotherapy that is emerging, new forms of adoptive immunotherapy are on the path of approval by regulatory authorities. At the decision-making level, a large somatic genetic analysis is becomin...
The following articles represent the first-place and runner-up winners from the NMCongress2017 poster contest. Both posters were presented and recognized at last year's conference. Congratulations to our winners!
Targeted therapy combination (TTC: antiRAF+antiMEK) is known to improve metastatic melanoma survival. Few severe skin toxicities (grade ≥3) are described with first-line TTC (17% for vemurafenib+cobimetinib and none for dabrafenib+trametinib) in a phase III trial. Among our 42 patients treated by TTC between January 2014 and March 2017, 4.8% (2/42) of those treated in the first line presented severe skin rash versus 19% (8/42) of patients treated in the second line after previous immunotherapy. In particu...
This mini-review highlights cardiovascular studies that were presented during the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting in Philadelphia. The aim of this review is to inform readers about several noteworthy studies reported at the meeting. Although cardiovascular application of PET and SPECT are not the primary focus of the SNMMI, several scientific teams working in this field presented their latest scientific findings at this meeting. The review therefore aims to info...
2018 Health Physics Society Military Health Physics Section John C. Taschner Leadership Award: Presented to CAPTAIN JOHN J. CARDARELLI II at the 63rd Annual Meeting of the Health Physics Society Cleveland, Ohio 15-19 July 2018.
The 54th Annual Meeting of the National Council on Radiation Protection and Measurements was held at the Hyatt Regency Bethesda, Maryland, on 5-6 March 2018. This annual meeting, entitled "Radiation Protection Responsibility in Medicine," was the first to deal entirely with radiation protection in medical imaging since the 43rd annual meeting in 2007 ("Advances in Radiation Protection in Medicine"). The 2018 meeting addressed updates for various modalities and included discussion on radiation dose metrics a...
Allergic rhinitis (AR) affects up to 40% of the United States population, with approximately $11 billion annual medical costs. Allergy immunotherapy is the best option for long-term symptomatic relief, but treatment compliance can be low. The objective was to describe subcutaneous immunotherapy (SCIT)-related costs for patients overall and those with inconsistent treatment.
The annual meeting of ASBMR was held in Montr?al Convention Center between September 28th and October 1st, 2018. Many scientific papers concerning bone, mineral metabolism, muscle and so on were presented as usual. There were several new attempts such as discussion about clinically difficult cases and sessions for young scientists in this meeting. I will introduce several papers concerning cancer treatment-induced bone loss and treatment of patients with PTH-deficient hypoparathyroidism.
This paper follows the immunotherapy symposium held during the European Association of Nuclear Medicine (EANM) 2017 Annual Congress. The biological basis of the immune checkpoint inhibitors and the drugs most frequently used for the treatment of solid tumours are reviewed. The issues of pseudoprogression (frequency, timeline), hyperprogression and immune-related side effects are discussed, as well as their implications for patient management. A review of the recent literature on the use of FDG PET for asses...